Unlock the research.
Expand patient access.
Psychedelic medicines are moving toward approval. Policy should open the door to research, affordable access and future treatment options, not narrow it.
The research is bigger than one indication.
Psychedelic research is exploring serious conditions with significant unmet need.
PTSD
Ongoing clinical investigation.Depression
A leading area of psychedelic research.Addiction
Alcohol, tobacco and opioid use research.Anorexia
Early clinical research is expanding.Chronic pain
An emerging area of investigation.Cancer related anxiety
Research in cancer related distress.These are areas of research and potential therapeutic investigation, not claims of approved uses. Research sources
Same molecule.
Two schedules.
FDA approval of a finished medicine does not necessarily move the underlying active ingredient out of Schedule I.
Recognized medical use
One finished product can become lawful under a less restrictive schedule.
Still treated as Schedule I
Research, formulation, supply, and broader medical innovation remain restricted.
That is bifurcated scheduling.
See the full explanation →Schedule I does more than label a molecule.
It shapes who can study it, who can work with it and how new treatment models can develop.
Schedule I controls add specialized registrations, protocols and handling requirements that can make studies harder to launch and scale.
If only a finished branded medicine moves schedules, broader medical pathways around the underlying molecule may remain constrained.
Future competition, formulation work and potential pharmacy pathways depend on what federal scheduling ultimately permits.
The case for access is already being made.
Legal, scientific and veteran leaders are already making the case for research, responsible access and a better path forward.
“I have not met a single person who can give me a legitimate reason why this shouldn’t happen.”Texas Law Magazine • Psilocybin Right to Try and rescheduling
“The need and urgency could not be greater than it is today.”Nevada Psychedelic Medicines Working Group
“Psychedelics [are] a paradigm shifting game changer in the treatment of mental health disorders.”Johns Hopkins Medicine • Public statement
“We need to do more research to understand this.”UCSF • Psilocybin and depression research
Placement imagery and public quotations are for design review. Final portraits, affiliations and presentation should be approved before launch and should not imply coalition membership or endorsement unless confirmed.
This fight already has a legal strategy.
Shane Pennington brings direct experience with the federal machinery the coalition is working to change.
“What right does the DEA have to tell this doctor what he can and cannot do, while he is in good faith trying to heal his patients?”
Draft positioning. Shane’s title, biography, portrait, Blank Rome affiliation, and public claims require Shane and Blank Rome approval before launch.
Shane's record →The decision has not been made yet.
The coalition's goal is to put bifurcated scheduling into the conversation before federal scheduling decisions lock in the wrong outcome.
Move the ingredient with the medicine.
When an FDA approved psychedelic medicine establishes accepted medical use, do not leave the bulk active ingredient in Schedule I through a brand only scheduling decision.
Homepage research areas are intentionally framed as active or emerging research, not approved indications. Final public version should link each condition to primary or institutional sources and use counsel approved language.
Patients should not have to wait for policy to catch up with science.
Help prevent bifurcated scheduling and protect the future of psychedelic medical research and access.
Prototype signup. Connect to coalition email platform before launch.